Complete report on Global Psoriasis Market Research with 222 market data tables and 17 figures, spread across 699 pages is available at http://www.reportsnreports.com/reports/729123-psoriasis-pipeline-review-h2-2016.html.
Company Analysis and Positioning discussed in this research are AbbVie Inc, Abeome Corporation, AbGenomics International, Inc., Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Affibody AB, Albireo AB, Almirall, S.A., Alteogen Inc., Amgen Inc., Anacor Pharmaceuticals, Inc., AnaptysBio, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Athenex, Inc., Aurigene Discovery Technologies Limited, Aurinia Pharmaceuticals Inc, Avexxin AS, Betta Pharmaceuticals Co. Ltd., BioApex, s.r.o., BIOCAD, Biocon Limited, BioLingus AG, BioMAS Ltd., Biomics Biotechnologies Co., Ltd., Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, CalciMedica, Inc., Can-Fite BioPharma Ltd., Celgene Corporation, Cell Medica Limited, Cellceutix Corporation, ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Clonz Biotech Private Limited, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Creabilis SA, Crescendo Biologics Limited, Curapel Limited, Cutanea Life Sciences, Inc., Dermala Inc, Domainex Limited, Dr. August Wolff GmbH & Co. , KG Arzneimittle, EA Pharma Co Ltd, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Exicure, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Gem Pharmaceuticals, LLC, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, GlycoMar Limited, Grupo Ferrer Internacional, S.A., HitGen LTD, Huabo Biopharm Co., Ltd., Hydra Biosciences, Inc., iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., Immune Pharmaceuticals Inc., Immune Response BioPharma, Inc., Immungenetics AG, Innovent Biologics, Inc., Jenrin Discovery, Inc., Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., KPI Therapeutics, Inc., Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, LEO Pharma A/S, Lipidor AB, Lupin Limited, Lycera Corp., mAbxience S.A., Maruho Co., Ltd., Medestea Research & Production S.p.A., MediGene AG, Merck KGaA, MetrioPharm AG, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., NeuClone Pty Ltd, Nimbus Therapeutics, LLC, NovaLead Pharma Pvt. Ltd., Novan, Inc., Novartis AG, Nuevolution AB, Numedii, Inc., Oncobiologics, Inc., OSE Immunotherapeutics, Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, Pieris Pharmaceuticals Inc, PinCell srl, Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Prothena Corporation Plc, Provectus Biopharmaceuticals, Inc., RedHill Biopharma Ltd., Rigel Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Selvita S.A., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Shulov Innovative Science Ltd., Sigmoid Pharma Limited, Soligenix, Inc., Spherium Biomed S.L., Stemline Therapeutics, Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Tasly Pharmaceutical Group Co., Ltd., Telormedix SA, Teva Pharmaceutical Industries Ltd., TheraMAB LLC, Therapeutic Proteins International, LLC, Therapix Biosciences Ltd., UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc., Wellstat Therapeutics Corporation, XBiotech Inc, XenoPort, Inc., Yuhan Corporation and Ziarco Pharma Ltd.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729123.
Psoriasis pipeline therapeutics constitutes close to 264 molecules. Out of which approximately 247 molecules are developed by Companies and remaining by the Universities/Institutes. Currently, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 39, 29, 2, 96, 37 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 7 molecules, respectively.
Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful Psoriasis drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies - such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd floor, metropole, Next to Inox theatre, Bund garden road
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml